On the other hand, m6A-modified CTLA-4 has been correlated with increased expression of CTLA-4 expression in gliomas, implicating that some tumors may exploit RNA modifications to gain a competitive advantage towards immune suppression rather than T-cell activation [42]. This evidence concerns the gene CTLA4 and glioma.